Novartis: positive results for pediatric multiple sclerosis.
(CercleFinance.com) - Novartis said on Tuesday that a phase III trial showed Gilenya, or fingolimod, significantly reduced relapses in children and adolescents with multiple sclerosis.
Data showed that orally administered fingolimod resulted in a significant and clinically meaningful reduction in the number of relapses over a period of up to two years, compared to interferon beta-1a intramuscular injections.
The study, investigating children and adolescents aged 10 to 17, was conducted in 87 sites over 25 countries.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
Data showed that orally administered fingolimod resulted in a significant and clinically meaningful reduction in the number of relapses over a period of up to two years, compared to interferon beta-1a intramuscular injections.
The study, investigating children and adolescents aged 10 to 17, was conducted in 87 sites over 25 countries.
Copyright (c) 2017 CercleFinance.com. All rights reserved.